News from polaris group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 22, 2020, 17:19 ET CMS Now Requires Health Care Workers to Receive Access to Long Term Care Facility Patients to Improve Resident Outcomes, Reports the Polaris Group

The Centers for Medicare & Medicaid Services (CMS) released a memorandum on Thursday, September 17 that requires Nursing Homes to permit access to...


Jul 09, 2018, 09:00 ET Polaris Announces Dr. Chi Van Dang Joining its Scientific Advisory Board

Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its...


Jul 08, 2018, 20:00 ET Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board

Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group), a biopharmaceutical company focused on developing novel drugs for cancer, announced...


Jun 05, 2018, 10:00 ET Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 in Metastatic Uveal Melanomas

Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that...


Jun 04, 2018, 10:00 ET Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 in Combination with Pembrolizumab For Advanced Solid Tumors

At the American Society Clinical Oncology's 2018 annual meeting, scientists from National Institute of Cancer Research Taiwan reported results from a ...


Jun 03, 2018, 10:00 ET Polaris Group Presents Results for Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI-PEG 20 Plus FOLFOX in Hepatocellular Carcinoma

Polaris Group announced results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with FOLFOX...


May 30, 2018, 10:06 ET Polaris Group Announces Treatment of First Patient in a Phase 2 Study of ADI-PEG 20 Plus Gemcitabine and Docetaxel for Soft Tissue Sarcoma

Polaris Group announced today that the first patient has been dosed in a phase 2 trial of ADI-PEG 20 in combination with gemcitabine and docetaxel...


May 10, 2018, 09:00 ET Polaris Signs Collaboration Agreement with MD Anderson Cancer Center to Join its Immunotherapy Platform for Clinical Trials and Preclinical Research

Polaris Group announced that it has signed a multiyear strategic Collaboration Agreement with MD Anderson Cancer Center to utilize its Immunotherapy...


Nov 08, 2016, 01:30 ET ADI-PEG 20 Radio-sensitizes Pancreatic Cancer Cells by Amplifying Early Endoplasmic Reticulum Stress

Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can selectively enhance the effect of...


Oct 24, 2016, 02:31 ET ADI-PEG 20 Can Boost Anti-Tumor Immune Surveillance

Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance...


Jun 06, 2016, 12:00 ET Polaris Group Reports Phase III Study Results of ADI-PEG 20 plus Best Supportive Care in Advanced Hepatocellular Carcinoma

Polaris Group announced today that the phase III study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care...


Jun 06, 2016, 12:00 ET FLT-PET Scan Provides Early Evidence of Response to Arginine Depletion by ADI-PEG 20 in Argininosuccinate Synthetase Deficient Thoracic Tumors

Polaris Group announced today that FLT-PET scan provided early evidence of response to arginine depletion by its lead therapeutic ADI-PEG 20...


Jun 03, 2016, 10:00 ET ADI-PEG 20 plus Gemcitabine and nab-Paclitaxel Shows Robust Anti-tumor Activity in Advanced Pancreatic Cancer

Polaris Group announced today results from an ongoing phase 1b study conducted at Memorial Sloan Kettering Cancer Center that tests combining ADI-PEG ...


Apr 18, 2016, 01:30 ET ADI-PEG 20 is a Potential Salvage Therapy for BRAFi Resistant Melanoma

Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, is a potential salvage therapy for BRAF...


Nov 11, 2015, 01:30 ET Polaris Group's ADI-PEG 20 Shows Robust Clinical Activity in Malignant Plural Mesothelioma and NSCLC When Combined with Standard First Line Chemotherapy Regimen

Polaris Group announced today the preliminary results from an ongoing phase 1 study that tests combining its lead therapeutic ADI-PEG 20 (pegylated...


Feb 03, 2015, 01:15 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus FOLFOX in Advanced Gastrointestinal Malignancies

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with folinic acid (leucovorin), ...


Dec 18, 2014, 01:30 ET Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma

Polaris Group announced today that its lead product candidate ADI-PEG 20 (pegylated arginine deiminase) has received orphan drug designation for the...


Dec 10, 2014, 01:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 Plus Sorafenib in Advanced Hepatocellular Carcinoma

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with sorafenib, a current first ...


Dec 03, 2014, 01:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with nab-paclitaxel and...


Dec 01, 2014, 01:30 ET Data Published by Researchers from Leading Cancer Institutes Show Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Causes Tumor Cytotoxicity through Previously Unidentified Mechanism

Polaris Group announced today that data from a recent publication in the Proceedings of the National Academy of Sciences of the USA (PNAS)...


Nov 20, 2014, 01:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin...


Nov 18, 2014, 01:30 ET Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Doxorubicin in HER2 Negative Breast Cancer

Polaris Group announced today that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with doxorubicin for the...


Apr 02, 2014, 05:00 ET Shaw T. Chen, M.D., Ph.D. joins Polaris

Polaris Group announced today that Shaw T. Chen, M.D., Ph.D. has joined Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group) as Executive...


Dec 02, 2013, 10:30 ET Polaris Group Files New IND for ADI-PEG 20 in Leukemia

Polaris Group announced today that it has filed an Investigational New Drug Application (IND) application with the United States Food and Drug...